![]() | Only 14 pages are availabe for public view |
Abstract Summary Neonatal sepsis defines the systemic condition that arises from the bacterial, viral or fungal origin, associated with hemodynamic changes and clinical findings and causing severe morbidity and mortality. Its incidence varies depending on the definition of the case and the population studied and is between 1 and 5 in 1000 live births. The clinical manifestations range from subclinical infection to severe focal or systemic disease. While the infectious agent may arise from intrauterine or maternal flora, it may also be of the hospital or community origin. NEC is one of the most common and serious acquired bowel diseases a newborn can face. Although it is not fully understood, the cause is suspected to be a combination of vascular necrosis, bacterial overgrowth and metabolic insults to the immature gut wall. Also, neonatal sepsis is a clinical syndrome of systemic illness accompanied by bacteremia occurring in the first month of life. Probiotics are defined as live non-pathogenic microbial supplements that colonies the gut while providing benefits to the host. They may prevent NEC and sepsis by promoting colonization with beneficial organisms, preventing colonization by pathogens improving the maturity and function of gut mucosal barrier in dealing with the flow of food and microbial antigens across it, and by modulating the immune system to the advantage of the host.This research sought to study the role of probiotics as a prophylactic therapy in decreasing the incidence and severity of neonatal sepsis and NEC. And in fact, probiotics supplementation has evidently reduced the incidence and severity of neonatal NEC, and it was associated with shorter duration of |